Literature DB >> 2959361

In vitro expression of secondary antitumor immunity by in vitro tumor-sensitized T cells: inhibition by tumor-induced suppressor T cells.

Z Kaymakcalan1, G L Spitalny, I Bursuker.   

Abstract

In vitro cultivation of memory immune cells from P815- or P388-immune mice with corresponding irradiated tumor cells induced generation of cytolytic T cells (CTL). The induction of CTL generation, as well as the cytolytic activity itself, was tumor-specific. The in vitro generation of CTL from P815- or P388-immune cells was suppressed by spleen cells from mice bearing corresponding progressive tumors (tumor size 15 mm). The tumor-induced suppressor cells suppressed the in vitro generation of CTL, but did not affect their cytolytic function. The suppression was tumor-specific and was mediated by Ly1+2-L3T4+ T cells. Treatment of suppressor cell donors with cyclophosphamide or sublethal gamma-radiation completely abolished the ability of their spleen cells to inhibit the in vitro CTL generation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959361     DOI: 10.1007/bf00199943

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

Review 2.  Down-regulation of the antitumor immune response.

Authors:  R J North
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

3.  Fractionation of lymphocyte populations with monoclonal antibodies specific for LYT-2.2 and LYT-3.1.

Authors:  D H Raulet; P D Gottlieb; M J Bevan
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

4.  Cytotoxic monoclonal antibody specific for the Lyt-1.2 antigen.

Authors:  C Mark; F Figueroa; Z A Nagy; J Klein
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

5.  Development of protective immunity against bacterial and viral infections in tumor-bearing mice coincident with suppression of tumor immunity.

Authors:  P F Bonventre; A D Nickol; E J Ball; J G Michael; H C Bubel
Journal:  J Reticuloendothel Soc       Date:  1982-07

Review 6.  Suppressor T cells and the immune response to tumors.

Authors:  S Schatten; R D Granstein; J A Drebin; M I Greene
Journal:  Crit Rev Immunol       Date:  1984       Impact factor: 2.214

Review 7.  Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity.

Authors:  D P Dialynas; D B Wilde; P Marrack; A Pierres; K A Wall; W Havran; G Otten; M R Loken; M Pierres; J Kappler
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

8.  Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors.

Authors:  I Bursuker; R J North
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.

Authors:  C D Mills; R J North
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

View more
  2 in total

1.  Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity.

Authors:  S K Hoover; S K Barrett; T M Turk; T C Lee; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.

Authors:  T H Inge; S K Hoover; J L Frank; T T Kawabata; K P Bethke; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.